Phlow secures $20 million to advance manufacturing initiatives in the US
The company seeks to actively accelerate US manufacturing for medicines at risk of shortage, including those for COVID-19 pandemic response
Pharma start-up Phlow Corporation has announced it has secured $20 million in a recent round of financing and said it will use the money to establish a commercial team, build data and analytics platforms, press on with commercial R&D of active pharmaceutical ingredients (APIs) and finished products, as well as funding other plans to deliver essential medicines.
Phlow, which was established to address the US supply chain's heavy dependence upon foreign suppliers, is using advanced manufacturing processes leveraging flow chemistry to produce active pharmaceutical ingredients (APIs) and finished pharmaceutical products, including those for COVID-19 pandemic response.
In May 2020, Phlow bagged a contract to manufacture generics and APIs in shortage, funded by Biomedical Advanced Research and Development Authority (BARDA), part of the office of Assistant Secretary for Preparedness and Response (ASPR) at the US Department of Health and Human Services (HHS).
The total contract value awarded to Phlow could reach $812 million; an initial four-year base award of $354 million with an additional $458 million bundled in as potential options for long-term sustainability. Under the terms of the agreement, Phlow is leading a team of private sector entities that includes API and intermediates manufacturer Ampac Fine Chemicals, Civica Rx and the Medicines for All Institute.
In its first contract year, Phlow said it has delivered millions of doses of essential medicines as part of a US-based, surge capacity ramp-up supporting critical COVID-19 response efforts while boosting the US's national supply chain security.
In addition, the company has developed and is operationalizing the US's first Strategic Active Pharmaceutical Ingredients Reserve (SAPIR). This long-term, national stockpile of key ingredients will be used to manufacture the most essential medicines on US soil and further reduce America's dependency on foreign nations to support its drug supply chain.
On its website, Virginia-based Phlow markets itself as a solution to a “broken” US pharmaceutical supply chain “dangerously dependent on foreign suppliers.” It says traditional batch manufacturing, which it describes as a multi-step, lengthy process that involves the use of large-scale, labour-intensive equipment, has led to API production being mainly centred in China and India, where labour costs are low.
The company says all its pharmaceutical products will be manufactured in the US by continuous manufacturing, which it describes as a modern process “that maximizes throughput, increases productivity, and lowers labour requirements.”
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance